Glutamate in schizophrenia: Clinical and research implications

Schizophrenia Research

Volumn 27, Issue 2-3, 1997, Pages 157-168

  Goff, Donald C ^a,b   Wine, Lara ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Freedom Trail Clinic   (United States)

Author keywords

Amino acids; D cycloserine; Glutamate; Glycine; Schizophrenia

Indexed keywords

AMPA RECEPTOR; ASPARTIC ACID; CLOZAPINE; CYCLOSERINE; DOPAMINE; EXCITATORY AMINO ACID; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; KAINIC ACID RECEPTOR; MESSENGER RNA; MILACEMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE; PLACEBO;

AGING; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; NEGATIVE SYNDROME; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

AGING; CITRIC ACID CYCLE; DOPAMINE; GLUTAMIC ACID; HUMANS; PHENCYCLIDINE; RECEPTORS, AMINO ACID; RECEPTORS, GLUTAMATE; SCHIZOPHRENIA;

EID: 0030773618     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(97)00079-0     Document Type: Conference Paper

References (93)

1. Akbarian, S., Smith, M.A., Jones, E.G., 1995. Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and scbizophrenia. Brain Res. 699, 297-304.
2. Akbarian, S., Sucher, N.J., Bradley, D. et al., 1996. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J. Neurosci. 16, 19-30.
3. Bakshi, V.P., Swerdlow, N.R., Geyer, M.A., 1994. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 271, 787-794.
4. Beal, M.F., 1992. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31, 119-130.
5. Bjerkenstedt, L., Edman, G., Hagenfeldt, L. et al., 1985. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br. J. Psychiatry 147, 276-282.
6. Breese, C.R., Freedman, R., Leonard, S.S., 1995. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res. 674, 82-90.
7. Brown, K. W., White, T., 1991. The association among negative symptoms, movement disorders, and frontal lobe psychological deficits in schizophrenic patients. Biol. Psychiatry 30, 1182-1190.
8. Carlsson, M., Carlsson, A., 1990. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13, 272-276.
9. Cascella, N.G., Macciardi, F., Cavallini, C. et al., 1994. D-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J. Neural Transm. Gen. Sect. 95, 105-111.
10. Choi, D.W., 1988. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1, 623-634.
11. Corbett, R., Camacho, R., Woods, A.T. et al., 1995. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 120, 67-74.
12. Costa, J., Khaled, E., Sramek, J. et al., 1990. An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics (letter). J. Clin. Psychopharmacol. 10, 71-72.
13. Court, J.A., Perry, E.K., Johnson, M. et al., 1993. Regional patterns of cholinergic and glutamatergic activity in the developing and aging human brain. Dev. Brain Res. 74, 73-82.
14. Coyle, J.T., 1996. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry 3, 241-253.
15. Coyle, J.T., Puttfarcken, P., 1993. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689-695.
16. Crane, G.E., 1959. Cycloserine as an antidepressant agent. Am. J. Psychiatry 115, 1025-1026.
17. Daly, D.A., Moghaddam, B., 1993. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci. Lett. 152, 61-64.
18. Deakin, J.F.W., Slater, P., Simpson, M.D.C. et al., 1989. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 52, 1781-1786.
19. Deutch, S.J., Mastropaolo, J., Schwartz, B.L. et al., 1989. A 'glutamatergic hypothesis' of schizophrenia. Clin. Neuropharmacol. 12, 1-13.
20. Deutch, A.Y., Tam, S.-Y., Freeman, A.S. et al., 1987. Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response. Eur. J. Pharmacol. 134, 257-264.
21. Eastwood, S.L., McDonald, B., Burnet, P.W.J. et al., 1995. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Mol. Brain Res. 29, 211-223.
22. Farber, N.B., Price, M.T., Labruyere, J. et al., 1993. Antipsychotic drugs block phencyclidine induced neurotoxicity. Biol. Psychiatry 34, 119-121.
23. Fitzgerald, L.W., Deutch, A.Y., Gasic, G. et al., 1995. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J. Neurosci. 15, 2453-2461.
24. Flood, J., Morley, J., Lanthorn, T., 1992. Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor. Eur. J. Pharmacol. 221, 249-254.
25. Gattaz, W.F., Gattaz, D., Beckmann, H., 1982. Glutamate in schizophrenics and healthy controls. Arch. Psychiatr. Nervenkr. 231, 221-225.
26. Goff, D.C., Tsai, G., Beal, M.F. et al., 1995a. Tardive dyskinesia and substrates of energy metabolism in CSF. Am. J. Psychiatry 152, 1730-1736.
27. Goff, D.C., Tsai, G., Levitt, J. et al., 1996a. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics. Paper presented at the American College of Neuropsychopharmacology, San Juan, Puerto Rico.
28. Goff, D.C., Tsai, G., Manoach, D.S. et al., 1995b. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry 152, 1213-1215.
29. Goff, D.C., Tsai, G., Manoach, D.S. et al., 1996b. D-Cycloserine added to clozapine for patients with schizophrenia. Am. J. Psychiatry 153, 1628-1630.
30. Grace, A.A., 1991. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia (review). Neuroscience 41, 1-24.
31. Grunze, H.C.R., Rainnie, D.G., Hasselmo, M.E. et al., 1996. NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci. 16, 2034-2043.
32. Handelmann, G., Nevins, M., Mueller, L. et al., 1989. Milacemide, a glycine pro-drug, enhances performance of learning tasks in normal and amnestic rodents. Pharmacol. Biochem. Behav. 34, 823-828.
33. Hanngren, H., Hansson, E., Ullberg, S., 1961. An autoradiographic study of the distribution of tritium-labeled cycloserine in mice. Antibiot. Chemother. 12, 46-54.
34. Harrison, P.J., McLaughlin, D., Kerwin, R.W., 1991. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 337, 450-452.
35. Hata, N., Nishikawa, T., Umino, A. et al., 1990. Evidence for involvement of N-methyl-D-aspartate receptor in tonic inhibitory control of dopaminergic transmission in rat medial frontal cortex. Neurosci. Lett. 120, 101-104.
36. Henderson, G., Johnson, J.W., Ascher, P., 1990. Competitive antagonists and partial agonists at the glycine modulatory site of the mouse N-methyl-D-aspartate receptor. J. Physiol. 430, 189-212.
37. Heresco-Levy, U., Javitt, D.C., Ermilov, M. et al., 1996. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry 169, 610-617.
38. Hollmann, M., Heinemann, S., 1994. Cloned glutamate receptors. Annu. Rev. Neurosci. 17, 31-108.
39. Huettner, J.E., 1990. Glutamate receptor channels in rat DRG neurons; activation by kainate and quisqualate and blockade of desensitization by Con A. Neuron 5, 255-266.
40. Huntley, G.W., Vickers, J.C., Morrison, J.H., 1994. Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: organizational features related to cortical circuitry, function and disease. Trends Neurosci. 17 (2), 536-543.
41. Imperato, A., Honore, T., Jensen, L.H., 1990. Dopamine release in the nucleus caudatus and accumbens is under glutamatergic control through non-NMDA receptors: a study in freely-moving rats. Brain Res. 530, 223.
42. Ishimaru, M., Kurumaji, A., Toro, M., 1994. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol. Psychiatry 35, 84-95.
43. Javitt, D.C., Zukin, S., 1991. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301-1308.
44. Javitt, D.C., Zylberman, I., Zukin, S.R. et al., 1994. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 151, 1234-1236.
45. Jedema, H.P., Moghaddam, B., 1994. Glutamatergic control of dopamine release during stress in the rat prefrontal cortex. J. Neurochem. 63, 785-788.
46. Kalivas, P., Duffy, P., Barrow, J., 1989. Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. J. Pharmacol. Exp. Ther. 251, 378-387.
47. Kerwin, R., Patel, S., Meldrum, B., 1990. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 39, 25-32.
48. Kerwin, R.W., 1993. Glutamate receptor, microtubule associated proteins and developmental anomaly in schizophrenia: an hypothesis. Psychol. Med. 13, 547-551.
49. Kerwin, R.W., Patel, S., Meldrum, B.S. et al., 1988. Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet 1, 583-584.
50. Kim, J.S., Kornhuber, H.H., Schmid-Burgk, W. et al., 1980. Low cerebrospinal glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20, 379-382.
51. Kirkpatrick, B., Buchanan, R., McKenney, P., 1989. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 30, 119-123.
52. Komuro, H., Rakic, P., 1993. Modulation of neuronal migration by NMDA receptors. Science 260, 95-97.
53. Korpi, E.R., Kaufmann, C.A., Marnela, K.M. et al., 1987. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res. 20, 337-345.
54. Krebs, M., Desce, J., Kemel, M. et al., 1991. Glutamatergic control of dopamine release in the rat striatum: evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals. J. Neurochem. 56, 81-85.
55. Krystal, J. H., Karper, L.P., Seibyl, J.P. et al., 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-214.
56. Lahti, A.C., Koffel, B., LaPorte, D. et al., 1995. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13, 9-19.
57. Lawlor, B.A., Davis, K.L., 1992. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? Biol. Psychiatry 31, 337-350.
58. Luby, E.D., Cohen, B.D., Rosenbaum, G. et al., 1959. Study of a new schizophrenomimetic drug - sernyl. Am. Med. Assoc. Arch. Neurol. Psychiatry 81, 363-369.
59. Macciardi, F., Lucca, A., Catalano, M. et al., 1990. Amino acid patterns in schizophrenia: some new findings. Psychiatry Res. 32, 63-70.
60. Maura, G., Giardi, A., Raiteri, M., 1988. Release-regulating D-2 dopamine receptors are located on striatal glutamatergic nerve terminals. J. Pharmacol. Exp. Ther. 247, 680-684.
61. 2+ of NMDA responses in spinal cord neurones. Nature 309, 261-263.
62. McDonald, J.W., Johnstone, M.V., 1990. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res. Rev. 15, 41-70.
63. Monahan, J., Handelmann, G., Hood, W. et al., 1989. D-Cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol. Biochem. Behav. 34, 649-653.
64. Mrzljak, L., Bergson, C., Pappy, M. et al., 1996. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. Nature 381, 245-248.
65. Murase, S., Grenhoff, J., Chouvet, G. et al., 1993. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studies in vivo. Neurosci. Lett. 157, 53-56.
66. 3H]Kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci. Lett. 40, 245-250.
67. Nowak, L., Bregestovski, P., Ascher, P. et al., 1984. Magnesium gates glutamate-activated channels in mouse central neurons. Nature 307, 462-465.
68. Olney, J.W., Farber, N.B., 1995. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52, 998-1007.
69. Ouagazzal, A., Nieoullon, A., Amalric, M., 1993. Effects of dopamine D1 and D2 receptor blockade on MK-801-induced hyperlocomotion in rats. Psychopharmacology 111, 427-434.
70. Perry, T.L., 1982. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci. Lett. 28, 83-85.
71. Rosse, R.B., Schwartz, B.L., Davis, R.E. et al., 1991. An NMDA intervention strategy in schizophrenia with 'low dose' milacemide. Clin. Neuropharmacol. 14, 268-272.
72. Rosse, R.B., Schwartz, B.L., Leighton, M.P. et al., 1990. An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy. Clin. Neuropharmacol. 13, 348-354.
73. Rosse, R.B., Theut, S.K., Banay, S.M. et al., 1989. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin. Neuropharmacol. 12, 416-424.
74. Sacaan, A.I., Bymaster, F.P., Schoepp, D.D., 1992. Metabotropic glutamate receptor activation produces extra-pyramidal motor system activation that is mediated by striatal dopamine. J. Neurochem. 59, 245-251.
75. Schinder, A.F., Olson, E.C., Spitzer, N.C. et al., 1996. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J. Neurosci. 16, 6125-6133.
76. Seeburg, P.H., 1993. The tips/tins lecture: the molecular biology of mammalian glutamate receptor channels. Trends Pharmacol. Sci. 14, 297-303.
77. Sekiguchi, M., Okamoto, K., Sakai, Y., 1989. N-Acetyl-aspartylglutamate suppresses the climbing fiber response of Purkinje cells in guinea pigs cerebellar slices and the responses to excitatory amino acids of Xenopus laevis oocytes injected with cerebellar mRNA. Brain Res. 482, 87-96.
78. Simeon, J., Fink, M., Itil, T. et al., 1970. d-Cycloserine therapy of psychosis by symptom provocation. Compr. Psychiatry 11, 80-88.
79. Taber, M.T., Fibiger, H.C., 1995. Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: modulation by metabotropic glutamate receptors. J. Neurosci. 15 (5), 3896-3904.
80. Toru, M., Kurumaji, A., Ishimaru, M., 1994. Excitatory amino acids: implications for psychiatric disorders research (review). Life. Sci. 55, 1683-1699.
81. Toru, M., Watanabe, S., Shibuya, H. et al., 1988. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr. Scand. 78, 121-137.
82. Toth, E., Lajtha, A., 1981. Elevation of cerebral levels of nonessential amino acids in vivo by administration of large doses. Neurochem. Res. 6, 1309-1317.
83. Trussel, L.O., Fishbach, G.D., 1989. Glutamate receptor desensitization and its role in synaptic transmission. Neuron 3, 209-218.
84. Tsai, G., Passani, L.A., Slusher, B.S. et al., 1995. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 52, 829-836.
85. Ulas, J., Cotman, C., 1993. Excitatory amino acid receptors in schizophrenia. Schizophr. Bull. 19, 105-117.
86. Verma, A., Moghaddam, B., 1996. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16 (1), 373-379.
87. Waddington, J.L., O'Callaghan, E., Larkin, C. et al., 1993. Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia. Brain Cogn. 23, 56-70.
88. Wang, J.K.T., 1991. Presynaptic glutamate receptors modulate dopamine release from striatal synaptosomes. J. Neurochem. 57, 819-822.
89. Watson, G.B., Bolanowski, M.A., Baganoff, M.P. et al., 1990. D-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res. 510, 158-160.
90. Waziri, R., 1988. Glycine therapy of schizophrenia (letter). Biol. Psychiatry 23, 209-214.
91. Weinberger, D., 1993. A connectionist approach to the prefrontal cortex. J. Neuropsychiatry 5, 241-253.
92. Yamamoto, B.K., Cooperman, M.A., 1994. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14, 4159-4166.
93. Youngren, K.D., Daly, D.A., Moghaddam, B., 1992. Distinct actions of endogenous excitatory amino acids on the outflow of dopamine in the nucleus accumbens. J. Pharmacol. Exp. Ther. 262, 289-293.